Alnylam Is Profitable, Growing 52%, and Still Being Priced Like a Broken Biotech

Alnylam's third quarter was, on paper, the best quarter in the company's history. Total revenue rose 67% year-over-year to roughly $1.3 billion of product alone, GAAP net income came in at $2.2 billion (inflated by a $1.9 billion non-cash tax valuation-allowance release), and cash climbed to $3.6 billion. Yet the stock sits 46% below its July 8 high of $323.50 and 65% below the October 2025 peak of $491.22, down 41% in ninety trading days. Nobody is arguing with the P&L. The argument is entirely about the slope — and this quarter management changed the slope, the trial, the KPI and the calendar all at once.

The demand that will not arrive on schedule

AMVUTTRA's ATTR-CM launch is 18 months old and, by management's own framing, underperforming its own investment case. The expanded field force has produced more physician engagement — more than 2,000 new unique prescribers, roughly a third of active prescribers having now tried the drug — but not more prescriptions. CEO Yvonne Greenstreet was blunt: “we're not yet satisfied with the underlying demand growth we have observed, and this is reflected in the full year outlook” — Yvonne Greenstreet, Chief Executive Officer · 2026-10-29. The mechanism, per Greenstreet, is that new prescribers arriving via the expanded sales force are lower-volume, less ATTR-literate, and slower to convert: “converting into patient starts is taking longer than we'd hoped” — Yvonne Greenstreet, Chief Executive Officer · 2026-10-29.

Watch what happened to the scoreboard. For several quarters the headline metric was new-to-brand share; this quarter Chief Commercialization Officer Tolga Tanguler shifted the emphasis to total prescriptions — 24% TRX share against a stable NBRx share north of 30% — explicitly flagging that "as launch matures, we will report on total prescriptions or TRXs." TRX share is a flattering number for a product with quarterly dosing and strong adherence, and it now carries the narrative. Meanwhile the underlying prescriber base is expanding faster than utilization inside it.

CFO Jeff Poulton then did something more consequential than guide down. He pushed product-revenue guidance to the low end of the $4.2–4.5 billion TTR range, warned that both inventory and price turn into Q4 headwinds, and deferred 2027 guidance away from JPMorgan for the first time in recent memory:

This would provide only a limited window between the effective date and the JPMorgan conference to observe how health systems are responding under the new framework. We will therefore not be providing 2027 product revenue guidance at JPMorgan as in past years, and instead expect to do so in conjunction with our fourth quarter and full year 2026 results in mid-February.

That is a company deliberately buying itself six weeks of information. It also repeats a pattern: on the July call Greenstreet opened with “Clearly, we're not pleased to be lowering guidance. As Jeff said, we own it.” — Yvonne Greenstreet, Chief Executive Officer · 2026-07-30 Two quarters, two effective downgrades, and the same explanation — engagement is rising, conversion is lagging.

340B: the word that ate the quarter

The genuinely new theme is not commercial at all. Alnylam's fresh keyword set is dominated by distribution plumbing that never appeared before: 340B institutions at the top of the list, site of care right behind it, alongside "viable path," "covered entities" and "340B channel." A proposed CMS rule would cut Medicare reimbursement for Part B drugs acquired through 340B, effective January 1, 2027 if finalized as proposed — and Alnylam will not size it. “It's a meaningful portion of our business. We're not going to get more explicit about it today” — Jeff Poulton, Chief Financial Officer · 2026-10-29, Poulton said, offering three provider responses: stay in 340B (net price down), shift to WAC purchasing (net price up), or move patients to alternate sites including home and third-party infusion clinics (net price up, volume uncertain). Layer on UnitedHealth's more restrictive first-line Medicare Advantage policy effective October 1, and you get Q4 ordering volatility from hospitals gaming the effective date.

The contrast with prior calls is stark. In February, Tanguler's pitch was that “the large majority of patients have first-line access to Amvuttra” — Tolga Tanguler, Head of Commercial or similar executive role · 2026-02-12 at zero out-of-pocket cost. Access was the moat. Two quarters later, patient access is the risk factor, and the company is negotiating contracting terms with the same health systems it once described as fully converted.

TRITON-CM blinks

The most telling line of the call was buried in R&D. Alnylam is adding 500 patients to TRITON-CM, taking it to roughly 2,250, because the standard of care keeps improving: earlier diagnosis and SGLT2 inhibitor background therapy are pushing cardiovascular event rates down. Pushkal Garg called it a secular trend: “these secular trends do tend to reduce event rates, which can compromise study power” — Pushkal Garg, Chief Research and Development Officer · 2026-10-29. The 2030 launch timing is unchanged.

Read against July, this is a reversal. Asked then whether TRITON-CM needed changes, Garg said “we may not need to do anything different from what we already have ongoing” — Pushkal Garg, Chief Research and Development Officer · 2026-07-30. It is at least the second enrollment enlargement, and it implicitly concedes that the original powering was calibrated to an event rate the real world no longer delivers. The tell is in the keyword set: HELIOS B, the top-ranked theme for Alnylam just one quarter ago and the evidentiary backbone of every prior call, has fallen out of the top thirty entirely. The company stopped leading with its own data and started defending its next trial.

What's left standing

The one unambiguously additive item is Huntington's. Brezosiran showed 60–64% mean maximum reductions in CSF mutant huntingtin, individual reductions to 83%, no dose-dependent CNS inflammatory signals and no neurofilament-light increases — targeting both full-length HTT and the shorter HTT1a isoform that rivals have missed. A placebo-controlled pivotal is planned for 2027 as an NDA. brezosiran is the only genuinely new growth vector on the call, and it is a 2027-and-beyond item.

Financially, the machinery is working even as the story wobbles. Revenue compounded from $225 million a quarter in 2022 to $1.29 billion in the latest reported period, and the balance sheet has healed: liabilities-to-assets has fallen from a 2023 peak of 107% to 76%. But margin is the quiet casualty of success — gross margin fell five points year-over-year to 72% on product sales purely because the Sanofi royalty escalates with volume. And the market has repriced accordingly: price-to-revenue has compressed to 8.4x, down 52% year-over-year. Analysts on the call pushed hard on whether the 25%+ revenue CAGR through 2030 still holds; Greenstreet re-affirmed it on a 75,000-patient U.S. treated pool and a one-third TRX share ambition, but the answer was aspiration, not arithmetic.

The bull case now rests on 2030 and a Huntington's franchise; the bear case is that 2027 arrives first, with a 340B rule nobody will quantify, a Medicare Advantage step edit already live, and a Phase III that keeps getting bigger to stay equally powered. Alnylam is no longer a launch story being mispriced. It is a company buying time — and this quarter it spent some.